BDTX Black Diamond Therapeutics Inc

Price (delayed)

$9.78

Market cap

$354.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.92

Enterprise value

$329M

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond ...

Highlights
The debt has declined by 3.1% since the previous quarter
Black Diamond Therapeutics's EPS has surged by 71% YoY but it has decreased by 23% QoQ
The net income has plunged by 129% YoY and by 23% from the previous quarter
The quick ratio has plunged by 66% YoY and by 28% from the previous quarter

Key stats

What are the main financial stats of BDTX
Market
Shares outstanding
36.21M
Market cap
$354.17M
Enterprise value
$329M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.41
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$105.19M
EBITDA
-$105.12M
Free cash flow
-$77.89M
Per share
EPS
-$2.92
Free cash flow per share
-$2.15
Book value per share
$6.94
Revenue per share
$0
TBVPS
$7.96
Balance sheet
Total assets
$287.88M
Total liabilities
$36.86M
Debt
$13.38M
Equity
$251.02M
Working capital
$247.46M
Liquidity
Debt to equity
0.05
Current ratio
11.54
Quick ratio
11.27
Net debt/EBITDA
0.24
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-32.9%
Return on equity
-36.1%
Return on invested capital
-38.1%
Return on capital employed
-39.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BDTX stock price

How has the Black Diamond Therapeutics stock price performed over time
Intraday
5.27%
1 week
2.52%
1 month
-1.71%
1 year
-67.02%
YTD
-69.49%
QTD
-19.77%

Financial performance

How have Black Diamond Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$107.09M
Net income
-$105.19M
Gross margin
N/A
Net margin
N/A
BDTX's operating income has shrunk by 131% YoY and by 23% QoQ
The net income has plunged by 129% YoY and by 23% from the previous quarter

Growth

What is Black Diamond Therapeutics's growth rate over time

Valuation

What is Black Diamond Therapeutics stock price valuation
P/E
N/A
P/B
1.41
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Black Diamond Therapeutics's EPS has surged by 71% YoY but it has decreased by 23% QoQ
The P/B is 55% lower than the last 4 quarters average of 3.0
The company's equity fell by 27% YoY and by 11% QoQ

Efficiency

How efficient is Black Diamond Therapeutics business performance
The ROA has shrunk by 70% YoY and by 29% QoQ
BDTX's return on invested capital is up by 43% year-on-year but it is down by 28% since the previous quarter
Black Diamond Therapeutics's ROE has decreased by 33% from the previous quarter and by 20% YoY

Dividends

What is BDTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BDTX.

Financial health

How did Black Diamond Therapeutics financials performed over time
The quick ratio has plunged by 66% YoY and by 28% from the previous quarter
BDTX's current ratio has dropped by 66% year-on-year and by 27% since the previous quarter
The debt is 95% smaller than the equity
The company's equity fell by 27% YoY and by 11% QoQ
The debt has declined by 3.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.